Ko­re­an biotech sees shares blitzed as its on­colyt­ic virus/Nex­avar com­bo fiz­zles in liv­er can­cer

An­oth­er Ko­re­an biotech is in trou­ble this morn­ing.

Sil­la­Jen set off shock waves in the sec­tor af­ter they filed no­tice that they are aban­don­ing a glob­al Phase III tri­al study­ing the im­pact of their on­colyt­ic virus Pexa-Vec with Nex­avar on liv­er can­cer. The in­de­pen­dent mon­i­tor­ing board says the com­bo failed their fu­til­i­ty test for the PHO­CUS study, their most ad­vanced de­vel­op­ment pro­gram, ad­vis­ing the com­pa­ny to give it up.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER